Helius Medical Technologies, Inc. HSDT NASDAQ · Financials · United States
$1.86 +1.64% +$0.03
Summary
54 / 100 · Bulios Score
What speaks for it
- Revenue grew by 97% a year over the last 3 years.
What to watch
- The company made a loss over the last 12 months.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 56% a year over 5 years. Over the last 3 years it grew by 97% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $157.3M.
Profitability in detailIs it financially healthy?
Banks and insurers work with their customers' money, so their debt is judged differently; see the health section for their capital figures.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 3
- Hold 2
- Sell 0
No analyst has published a price target.
60% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 77%
- Product and Service, Other 23%
By region
- UNITED STATES 55%
- CANADA 45%
Product brings in 77% of revenue.
Segments in detail